Peter J. Houghton
Department of Molecular Pharmacology
St. Jude Children's Research Hospital
Memphis
Tennessee 38105
USA
Name/email consistency: high
- Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Houghton, P.J., Morton, C.L., Kang, M., Reynolds, C.P., Billups, C.A., Favours, E., Payne-Turner, D., Tucker, C., Smith, M.A. Pediatr. Blood. Cancer (2010)
- Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Houghton, P.J., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wu, J., Smith, M.A. Pediatr. Blood. Cancer (2010)
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. Pediatr. Blood. Cancer (2008)
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Houghton, P.J., Morton, C.L., Kolb, E.A., Lock, R., Carol, H., Reynolds, C.P., Keshelava, N., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. Pediatr. Blood. Cancer (2008)
- The pediatric preclinical testing program: description of models and early testing results. Houghton, P.J., Morton, C.L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E.A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Courtright, J., Keir, S.T., Friedman, H.S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C.A., Khan, J., Ansher, S., Zhang, J., Smith, M.A. Pediatr. Blood. Cancer (2007)
- mTOR as a target for cancer therapy. Houghton, P.J., Huang, S. Curr. Top. Microbiol. Immunol. (2004)
- Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler, P. Cancer Res. (2004)
- Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Houghton, P.J., Stewart, C.F., Cheshire, P.J., Richmond, L.B., Kirstein, M.N., Poquette, C.A., Tan, M., Friedman, H.S., Brent, T.P. Clin. Cancer Res. (2000)
